Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) traded down 1% during mid-day trading on Wednesday . The stock traded as low as $1.51 and last traded at $1.52. 12,465 shares were traded during trading, a decline of 21% from the average session volume of 15,759 shares. The stock had previously closed at $1.53.
Humacyte Price Performance
The business has a fifty day moving average of $1.64 and a 200-day moving average of $1.94.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Recommended Stories
- Five stocks we like better than Humacyte
- What Does Downgrade Mean in Investing?
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Why is the Ex-Dividend Date Significant to Investors?
- 3 Steel Stocks Soaring After Tariff Announcements
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png?v=20230920074015&h=45&w=95&zc=2){kind=logo}
